Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Migraine Drug Atogepant Delivers Good News When Allergan Needs It Most

Oral CGRP inhibitor atogepant delivers strong Phase IIb/III results in episodic migraine prevention less than a week after activist investors went public with their push for a management shakeup to reverse Allergan's falling stock price.

Clinical Trials Neurology Research and Development Strategies
Advertisement

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO

With Merck's Keytruda on top of the world and setting the standard for PD-1/L1 lung cancer data, Roche and Bristol defended the programs for their competing Tecentriq and Opdivo during ASCO investor events.

Market Intelligence ImmunoOncology

Merck's Keytruda Monotherapy May Get Stuck With Small Role In First-line Lung Cancer

As results for KEYNOTE-042 are reported at ASCO, Merck's Roy Baynes says Keytruda plus chemotherapy is the standard of care in first-line non-small cell lung cancer, but Keytruda monotherapy is an option for those who don't tolerate chemo well and/or don't have very active disease.

ImmunoOncology Clinical Trials

J&J Muscles Into CAR-T Field: Initiates Myeloma Studies

An autologous CAR-T therapy in development by Janssen and Legend Biotech is expected to kick-off US clinical studies in the second half of 2018, adding to the race to apply the new technology to multiple myeloma.

Clinical Trials ImmunoOncology

Pfizer's Xeljanz Pushed By New Tailwind From Approval In Ulcerative Colitis

FDA approved the JAK inhibitor as the first oral medicine for moderate to severe ulcerative colitis, providing Pfizer with fertile new commercial ground for the blockbuster drug.

Approvals Gastrointestinal

Tomorrow’s CRO Steps Into The Real World

Last year, 187 deals took place in the pharma services realm, each one molding the acquisitive company into a slightly different shape to reflect the current needs of the pharmaceutical industry. One imperative continued to drive more large deals than all others: data.

Research and Development Strategies Deals

Dupixent Hits Endpoints In Adolescents, Filing Expected In Q3

Positive top-line Phase III results have been released on the use of Sanofi/Regeneron's Dupixent in adolescents with moderate-to-severe atopic dermatitis, adding to the evidence supporting its use in adults.

Dermatology Clinical Trials
See All
UsernamePublicRestriction

Register